Transgenic plants present enormous potential to become one of the most cost-effective and safe systems for large-scale production of proteins for industrial, pharmaceutical, veterinary, and agricultural uses. Over the past decade, much progress has been made with respect to the development of vaccines, antibodies, and other therapeutic proteins. Bi

Kathleen Laura Hefferon achieved her Ph.D. at the University of Toronto. She most recently held the title of Director of Operations of the Human Metabolic Research Unit in the Division of Nutritional Sciences at Cornell University. She also acts as a science writer for the Center for Hepatitis C Research at Rockefeller University in New York City and as an expert selector for the Infection and Immunity Division of the Medical Research Council, in London.